患者特异性心脏约束优化乳腺癌平均心脏剂量
该研究回顾性分析264例接受全乳放疗同步加量患者,比较引入患者特异性心脏约束(PSHC)前后平均心脏剂量(MHD)变化。结果显示PSHC显著降低右侧和左侧治疗的MHD及心脏V5 Gy,左侧自由呼吸获益最大,且所有计划靶区剂量均达标。
要点
- PSHC可显著降低乳腺癌放疗的MHD和心脏V5 Gy。
- 左侧自由呼吸治疗MHD降低最明显(-1.2 Gy)。
- 所有计划肿瘤床剂量均高于54.15 Gy阈值。
核心结论
- 引入PSHC可降低全乳放疗同步加量患者的MHD和V5 Gy,同时维持计划剂量学质量。
- 左侧自由呼吸治疗获益最大。
研究设计与样本
- 回顾性队列研究,264例患者分为PSHC引入前(138例)和引入后(126例)两组。
- 处方剂量:乳腺PTV 50 Gy,同步加量PTV 57 Gy,分25次。
- 计划采用混合IMRT技术:30 Gy开放切线野,27 Gy IMRT野。
- PSHC计算公式为开放切线野MHD×2。
主要发现
- 总体MHD右侧降低-0.4 Gy(P<.0001),左侧降低-1.2 Gy(P<.0001)。
- 左侧自由呼吸MHD降低-0.46 Gy(P=.34),无统计学显著性。
- 心脏V5 Gy右侧降低-1%(P=.002),左侧降低-9.2%(P<.0001)。
- 左侧自由呼吸V5 Gy降低-8.8%(P<.0001),DIBH降低-5.1%(P=.0034)。
- 所有计划肿瘤床剂量均高于54.15 Gy(57 Gy的95%)。
关键数值与推荐
- MHD约束为4 Gy。
- 肿瘤床剂量阈值54.15 Gy(95% of 57 Gy)。
- PSHC=开放切线野MHD×2。
临床怎么用
- 可在IMRT优化前计算PSHC以预测MHD并辅助优化。
- 对左侧自由呼吸乳腺癌患者,PSHC降低心脏剂量获益最明显。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Our institution introduced a patient-specific heart constraint (PSHC) and a mean heart dose (MHD) constraint of 4 Gy for all patients receiving breast radiation therapy (RT) with a simultaneous boost (SIB). This was introduced as a method to calculate the predicted MHD before optimizing IMRT fields. We sought to determine whether the introduction of a PSHC reduced MHD, while maintaining optimally dosed treatment plans. MATERIAL/METHODS: Patients were retrospectively divided into 2 groups, pre- and postintroduction of the PSHC. The breast and SIB Planning Target Volumes (PTVs) were prescribed to 50 Gy and 57 Gy, respectively, in 25 fractions. Plans were generated using a hybrid IMRT technique, 30 Gy using an open tangential field arrangement, and 27 Gy using IMRT fields. The PSHC was calculated using MHD of open tangential field × 2. A paired t test compared PTV coverage and heart doses between cohorts (P < .05 significant). RESULTS: A total of 264 patients were included (138 pre-PSHC and 126 post-PSHC) with 137 right-sided and 127 left-sided treatments. MHD was significantly reduced across both right-sided (-0.4 Gy, P < .0001) and left-sided (-1.2 Gy, P < .0001) treatments overall. Left-sided treatments were further examined between free breathing and deep inspiration breath-hold (DIBH). DIBH showed reduction in MHD, although it was not significant (-0.46 Gy, P = .34). Heart V5 Gy showed reduction in right-sided (-1%, P = .002) and left-sided (-9.2%, P < .0001) treatments overall. Left-sided free breathing showed significant reduction (-8.8%, P < .0001), and DIBH also showed significant reduction (-5.1%, P = .0034). Tumor bed doses remained above the 54.15 Gy (95% of 57 Gy) threshold for all plans. CONCLUSION: Introduction of a PSHC can reduce MHD and V5 Gy for patients receiving whole breast RT with SIB while maintaining optimally dosed plans, with the greatest benefit shown for left-sided, free-breathing treatments.
引用
- Ward R, West K, Latty D, et al. Patient-Specific Heart Constraint: A Tool for Optimization and Evaluation of Mean Heart Dose in Breast Cancer Patients. Pract Radiat Oncol. 2020. PMID: 33130033. doi:10.1016/j.prro.2020.10.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。